OBJECTIVES: Patients receiving LB during their TKA procedure have greater and earlier mobility while also having a shorter length of stay (LOS) than those with usual care during TKA.  It is unknown if these advances with LB in the TKA population result in similar long-term outcomes. The objective of this study was to determine the long-term outcomes for patients receiving LB during their TKA procedure. METHODS: From Sept 2013 to Apr 2014, consecutively recruited 134 TKA patients received a single LB 20ml, bupivacaine 0.25% with epinephrine 30ml, normal saline injectable that was administered intra-operatively and delivered via local infiltration. A historical cohort of 134 TKA patients with usual care (Oct 2011 to Aug 2013) were propensity-score matched by their clinical and demographic characteristics. Primary outcomes included pain intensity, pain interference, and physical function, which were collected through Patient Reported Outcomes Measurement Information System (PROMIS) survey at >6 months after surgery. PROMIS T-scores were compared to a standardized population (SP) score (mean±SD) 50±10. Secondary outcome included 30-day readmission. Other variables included demographics, comorbidity, distance walked, LOS, and discharge destination. Sample size was powered 0.80 and alpha 0.05.  RESULTS: Among 154 patients included (60% response), the majority were female (57%), >60 years old (80%), obese (62%) and discharged to home (83%). T-scores of primary outcomes were similar between cases and controls (p>0.05): pain intensity (mean±SD) 36.8±7.2 vs. 35.4±7.0, pain interference 46.6±6.7 vs. 45.3±7.25, and physical function 46.8±6.9 vs. 48.2±8.3. Cases and controls had pain intensity scores 1.5 SD lower than the SP while pain interference and physical function scores were similar to the SP score. The 30-day readmission rates were similar between cases (3%) and controls (5%). CONCLUSIONS: Receiving a LB injectable suspension did not affect long-term outcomes. Patients with a TKA in case and control groups demonstrated improved pain score compared to the general population.